Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Test af den potentielle metaboliske virkning af det humane tarmbakteriepeptid, Rucilp, hos raske mænd

28. september 2026 opdateret af: Oluf Pedersen

The goal of this randomized, double-blinded and placebo-controlled clinical cross-over trial is in healthy men to explore the potential metabolic effects of the naturally occurring gut bacterial polypeptide, RUCILP. This bacterial peptide is produced by commensal strains of Ruminococcus torques in the human gut microbiota.

In preclinical studies of rodents, RUCILP lowers blood glucose and stimulates release of plasma insulin, glucagon-like peptide-1(GLP-1) and Peptide YY (PYY) but induces a decline of glucose-dependent insulinotropic polypeptide (GIP).

In the present trial, the investigators want to explore potential effects of intraduodenally delivered RUCILP on release of plasma concentrations of GLP-1, GIP and PYY.

In addition, the investigators will test for potential effects of intestinal RUCILP infusion on plasma concentrations of glucose, insulin and metabolome.

Participants will have a duodenal tube placed into which RUCILP or placebo will be infused over 3 hours after an initial standardized liquid meal infusion into the duodenal tube.

Participants will on different days and in a randomized order receive either placebo or RUCILP infusion into the tube.

Safety is acutely monitored under the intervention and postintervention safety is monitored by clinical biochemistry measures of hematology, and liver and kidney functions. The study participants will further keep a diary of any experienced adverse effects during the week after the intervention.

Primary OUTCOMES: a composite of changes in plasma concentrations of GLP-1, GIP and PYY.

Secondary OUTCOMES: changes in plasma glucose, plasma insulin and plasma metabolome profile.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

17

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Hellerup, Danmark, 2900
        • Gentofte Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 35 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 35 years
  • Self-reported good health
  • Caucasian
  • Normal body mass index (18.5 to <25)

Exclusion Criteria:

  • Any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease.
  • Use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial
  • Use of antibiotics during the recent three months
  • Acute or chronic gastrointestinal symptoms
  • Lactose intolerance
  • Smoking
  • Alcohol or drug abuse
  • Use of creatine as dietary supplement during study period
  • Plasma creatinine concentration above the normal range (>105 μmol/L)
  • Known significant liver disease or plasma ALAT concentration ≥ 3 × normal value
  • Values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Placebo comparator that is identical to the active arm except for the absence of RUCILP

Placebo is identical to the active intervention except for the absence of the RUCILP molecule.

Aktiv komparator: Active

Intervention is identical to the placebo arm except for the addition of RUCILP to the infusion.

The naturally occuring gut peptide RUCILP synthesized by the commensal gut bacterium Ruminococcus torques

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma concentrations of GIP
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of GIP at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion
Plasma concentrations of GLP-1
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of GLP-1 at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion
Plasma concentrations of PYY
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of PYY at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma concentrations of insulin
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of insulin at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion
Plasma concentrations of glucose
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of glucose at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion
Plasma metabolome profile
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma metabolome profile at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion
Plasma concentrations of RUCILP
Tidsramme: During the 3 hours of RUCILP/placebo infusion

Plasma measurements of RUCILP at different time points during the study day.

During the 3 hours of RUCILP/placebo infusion

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Estimeret glomerulær filtreringshastighed (EGFR)
Tidsramme: Ved baseline, 180 minutter og ved opfølgning (4-8 dage efter studiedagen)
Ved baseline, 180 minutter og ved opfølgning (4-8 dage efter studiedagen)
Blood leukocytes
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of leukocytes in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Blood eosinophils
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of eosinophils in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Total blood leukocytes
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of total leukocytes in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Blood neutrophils
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of neutrophils in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Blood platelets
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of platelets in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Blood hemoglobin
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of hemoglobin in blood

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma alanine transaminase (ALT)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of alanine transaminase (ALT) in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma aspartate transferase (AST)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of aspartate transferase (AST) in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma alkaline phosphatase
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of alkaline phosphatase in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma albumin
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of albumin in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma creatinine
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of creatinine in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma sodium
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of sodium in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma potassium
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of potassium in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma calcium (total)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of total calcium in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma phosphate
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of phosphate in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma creatine kinase
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of creatine kinase in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Plasma C-reactive protein
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)

Concentration of C-reactive protein in plasma

At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
Experienced adverse effects post infusion
Tidsramme: At 180 minutes.

Number of experienced adverse effects as noted in a diary at end of each study day.

At 180 minutes.
Experienced adverse effects during the four days following an infusion
Tidsramme: During four days of follow-up after each study day.

Number of experienced adverse effects as noted in a diary during four days of follow-up after each infusion.

During four days of follow-up after each study day.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. juli 2025

Primær færdiggørelse (Faktiske)

27. august 2025

Studieafslutning (Faktiske)

4. september 2025

Datoer for studieregistrering

Først indsendt

20. marts 2025

Først indsendt, der opfyldte QC-kriterier

4. april 2025

Først opslået (Faktiske)

11. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. april 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • H-22011935

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Due to GDPR regulations we are unable to share IPD with other researchers.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .